SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Johansen J. D.)
 

Sökning: WFRF:(Johansen J. D.) > (2000-2004) > Budesonide and form...

Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma

Lalloo, UG (författare)
Malolepszy, J (författare)
Kozma, D (författare)
visa fler...
Krofta, K (författare)
Ankerst, Jaro (författare)
Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
Johansen, B (författare)
Thomson, NC (författare)
visa färre...
 (creator_code:org_t)
2003
2003
Engelska.
Ingår i: Chest. - 1931-3543. ; 123:5, s. 1480-1487
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: We evaluated the efficacy and safety of low-dose budesonide/formoterol, 80 mug/4.5 mug, bid in a single inhaler (Symbicort Turbuhaler; AstraZeneca; Lund, Sweden) compared with an increased dose of budesonide, 200 mug bid, in adult patients with mild-to-moderate asthma not fully controlled on low doses of inhaled corticosteroid alone. Methods: All patients received budesonide, 100 jig bid, during a 2-week run-in period. At the end of the run-in phase, 467 patients with a mean FEV1 of 82% predicted received 12 weeks of treatment with budesonide/formoterol in a single inhaler or budesonide alone in a higher dose. Patients kept daily records of their morning and evening peak expiratory flow (PEF), nighttime and daytime symptom scores, and use of reliever medication. Results: The increase in mean morning PEF-the primary efficacy measure-was significantly higher for budesonide/formoterol compared with budesonide alone (16.5 L/min vs 7.3 L/min, p = 0.002). Similarly, evening PEF was significantly greater in the budesonide/formoterol group (p < 0.001). In addition, the percentage of symptom-free days and asthma-control days (p = 0.007 and p = 0.002, respectively) were significantly improved in the budesonide/formoterol group. Budesonide/formoterol decreased the relative risk of an asthma exacerbation by 26% (p = 0.02) compared with budesonide alone. Adverse events were comparable between the two treatment groups. Conclusion: This study shows that in adult patients whose mild-to-moderate asthma is not fully controlled on low doses of inhaled corticosteroids, single-inhaler therapy with budesonide and formoterol provides greater improvements in asthma control than increasing the maintenance dose of inhaled corticosteroid.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)

Nyckelord

formoterol
inhaled corticosteroids
long-acting
beta(2)-agonists
Symbicort
asthma
budesonide

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

  • Chest (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy